Stocktoria
Nuvation Bio Inc. NUVB
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2020-07-01
Nuvation Bio Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0 | — | — |
| Gross profit | — | $795,000 | $0 | — | — |
| R&D expense | $115.1M | $99.1M | $71.3M | $87.8M | $69.0M |
| SG&A expense | $151.6M | $69.2M | $28.5M | — | — |
| Operating income | -$213.1M | -$592.6M | -$99.8M | -$119.7M | -$93.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$204.6M | -$567.9M | -$75.8M | -$104.2M | -$86.8M |
| EPS (diluted) | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 |
| Operating cash flow | -$173.4M | -$130.4M | -$68.0M | -$96.1M | -$68.2M |
| Cash & equivalents | $164.1M | $35.7M | $42.6M | $101.1M | $132.4M |
| Inventory | $11.4M | $0 | — | — | — |
| Total assets | $594.8M | $540.6M | $621.5M | $672.1M | $776.2M |
| Total liabilities | $289.1M | $76.8M | $16.4M | $17.1M | $30.2M |
| Shareholders' equity | $305.7M | $463.8M | $605.1M | $655.1M | $746.0M |
Source: SEC EDGAR filings · CIK 0001811063 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.